A Multicenter Evaluation of the Safety of Drotrecogin Alfa (Activated) in Patients with Baseline Bleeding Precautions

E-ISSN： 2212-3911|7|1|3-7

ISSN： 1574-8863

Source： Current Drug Safety, Vol.7, Iss.1, 2012-02, pp. : 3-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

International integrated database for the evaluation of severe sepsis (INDEPTH): clinical evaluation committee report on the safety of drotrecogin alfa (activated) therapy

By Dhainaut Jean-François

Current Medical Research and Opinion, Vol. 24, Iss. 4, 2008-04 ,pp. : 1187-1197

Informa Healthcare

Access to resources Recommend Favorite

Safety of drotrecogin alfa (activated): a fair comparison requires consistent definitions

By Williams Mark Macias William Rustige Joerg

Intensive Care Medicine, Vol. 33, Iss. 8, 2007-08 ,pp. : 1487-1488

Springer Publishing Company

Access to resources Recommend Favorite

Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study

By Kanji Salmaan Perreault Marc Chant Clarence Williamson David Burry Lisa

Intensive Care Medicine, Vol. 33, Iss. 3, 2007-03 ,pp. : 517-523

Springer Publishing Company

Access to resources Recommend Favorite

International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH

By Sashegyi Andreas Trzaskoma Benjamin L. Nelson David R. Williams Mark D. Macias William

Current Medical Research and Opinion, Vol. 22, Iss. 5, 2006-05 ,pp. : 1001-1012

Informa Healthcare

Access to resources Recommend Favorite

When a single pivotal trial should not be enough–the case of drotrecogin-alfa (activated)

By Wiedermann Christian

Intensive Care Medicine, Vol. 32, Iss. 4, 2006-04 ,pp. : 604-604

Springer Publishing Company

Access to resources Recommend Favorite